Jiaming Cui, Jack Heavey, Eili Klein, Gregory R. Madden, Costi D. Sifri, Anil Vullikanti, B. Aditya Prakash
{"title":"Identifying and forecasting importation and asymptomatic spreaders of multi-drug resistant organisms in hospital settings","authors":"Jiaming Cui, Jack Heavey, Eili Klein, Gregory R. Madden, Costi D. Sifri, Anil Vullikanti, B. Aditya Prakash","doi":"10.1038/s41746-025-01529-x","DOIUrl":null,"url":null,"abstract":"<p>Healthcare-associated infections (HAIs) from multi-drug resistant organisms (MDROs) pose a significant challenge for healthcare systems. Patients can arrive at hospitals already infected (\"importation”) or acquire infections during their stay (\"nosocomial infection”). Many cases, often asymptomatic, complicate rapid identification due to testing limitations and delays. Although recent advancements in mathematical modeling and machine learning have aimed to identify at-risk patients, these methods face challenges: transmission models often overlook valuable electronic health record (EHR) data, while machine learning approaches typically lack mechanistic insights into underlying processes. To address these issues, we propose NeurABM, a novel framework that integrates neural networks and agent-based models (ABM) to leverage the strengths of both methods. NeurABM simultaneously learns a neural network for patient-level importation predictions and an ABM for infection identification. Our findings show that NeurABM significantly outperforms existing methods, marking a breakthrough in accurately identifying importation cases and forecasting future nosocomial infections in clinical practice.</p>","PeriodicalId":19349,"journal":{"name":"NPJ Digital Medicine","volume":"8 1","pages":""},"PeriodicalIF":12.4000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Digital Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41746-025-01529-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Healthcare-associated infections (HAIs) from multi-drug resistant organisms (MDROs) pose a significant challenge for healthcare systems. Patients can arrive at hospitals already infected ("importation”) or acquire infections during their stay ("nosocomial infection”). Many cases, often asymptomatic, complicate rapid identification due to testing limitations and delays. Although recent advancements in mathematical modeling and machine learning have aimed to identify at-risk patients, these methods face challenges: transmission models often overlook valuable electronic health record (EHR) data, while machine learning approaches typically lack mechanistic insights into underlying processes. To address these issues, we propose NeurABM, a novel framework that integrates neural networks and agent-based models (ABM) to leverage the strengths of both methods. NeurABM simultaneously learns a neural network for patient-level importation predictions and an ABM for infection identification. Our findings show that NeurABM significantly outperforms existing methods, marking a breakthrough in accurately identifying importation cases and forecasting future nosocomial infections in clinical practice.
期刊介绍:
npj Digital Medicine is an online open-access journal that focuses on publishing peer-reviewed research in the field of digital medicine. The journal covers various aspects of digital medicine, including the application and implementation of digital and mobile technologies in clinical settings, virtual healthcare, and the use of artificial intelligence and informatics.
The primary goal of the journal is to support innovation and the advancement of healthcare through the integration of new digital and mobile technologies. When determining if a manuscript is suitable for publication, the journal considers four important criteria: novelty, clinical relevance, scientific rigor, and digital innovation.